The metabolism of cholesterol by cytochrome P450 side chain cleavage enzyme is hormonally regulated in steroidogenic tissues via intramitochondrial cholesterol transport. The mediating steroidogenic acute regulatory protein (StAR) is synthesized as a 37-kDa (p37) precursor that is phosphorylated by protein kinase A and cleaved within the mitochondria to generate 30-kDa forms (p30, pp30). The effectiveness of modified recombinant StAR forms in COS-1 cells without mitochondrial import has led to a prevailing view that cholesterol transport is mediated by p37 StAR via activity on the outer mitochondrial membrane. The present study of the activation of cholesterol metabolism by bromo-cAMP in adrenal cells in relation to 35 S-StAR turnover indicates that targeting of pp30 to the inner membrane provides the dominant cholesterol transport mechanism. We show that 1) only newly synthesized StAR is functional, 2) phosphorylation and processing of p37 to pp30 occurs rapidly and stoichiometrically, 3) both steps are necessary for optimum transport, and 4) newly synthesized pp30 exhibits very high activity (400 molecules of cholesterol/StAR/min). Segregation of cAMP activation and synthesis of StAR from cholesterol metabolism showed that very low levels of newly synthesized StAR (1 fmol/min/10 6 cells) sustained activated cholesterol metabolism (0.4 pmol/min/10 6 cells, t1 ⁄2 ‫؍‬ 70 min) long after complete removal of p37 (t1 ⁄2 ‫؍‬ 5 min). This activity was highly sensitive to inhibition of processing by CCCP only until sufficient pp30 was formed. Maximum activation preceded bromo-cAMP-induced StAR expression, indicating other limiting steps in cholesterol metabolism.
The conversion of cholesterol to pregnenolone, the first step in steroid synthesis, is catalyzed by cytochrome P450 side chain cleavage enzyme (P450scc), 1 which is localized on the matrix side of the inner mitochondrial membrane (1, 2) . The transfer of cholesterol to P450scc, a limiting step in this conversion (3, 4) , requires hormonal activation of cholesterol mobilization to the mitochondria. This mobilization is dependent on the uptake of lipoproteins, lysosomal-cytosolic transfer, and hydrolysis of cholesterol esters as well as on two subsequent transfer steps (5) . The first step involves transfer of cholesterol to the mitochondria and is dependent on an intact cytoskeleton but not on protein synthesis (6) . The second step involves transfer within the mitochondria from outer to inner membrane. This trophic hormone-dependent transport of cholesterol from mitochondrial outer membrane to inner membrane (4, 7, 8) is blocked in vivo within 10 min by protein synthesis inhibitors, such as cycloheximide (CHX) (9, 10) . A series of cAMP-stimulated and CHX-sensitive phosphoproteins (30) (31) (32) (33) (34) (35) (36) (37) , which localize to the mitochondria, have been identified in cultured adrenal and testis cells (11) (12) (13) (14) (15) (16) (17) . The gene that encodes these proteins has been cloned, and the active form has been named the steroidogenic acute regulatory protein (StAR) (18) . The expression of recombinant StAR in modified COS-1 cells enhances cholesterol metabolism (19) , even when StAR is mutated to prevent the mitochondrial uptake of the protein (20) . This has raised essential questions concerning the role of N-terminal processing in the activity of StAR. Deletions or mutations of StAR (all C-terminal) have been found in humans born with the steroid deficiency disease, lipoid adrenal congenital hyperplasia (21) (22) (23) . Disruption of the StAR gene in mice produces a similar phenotype (24) . The effect of these deletions establishes that StAR is necessary for 80 -90% of adrenal cholesterol metabolism. StAR is selectively expressed in all steroidogenic tissues, except the placenta (25) . The latter may express another StAR family member, such as has been cloned from mammary cells (26) .
Before the cloning of StAR, co-translational phosphorylation of the precursor protein (p37), followed by rapid intramitochondrial turnover was suggested as a reason for the rapid effect of protein synthesis inhibitors (11, 13) . Transfer of the positively charged leader sequence through the import pore requires a mitochondrial membrane potential and is linked to a matrix proteolytic cleavage of the leader sequence (27) (28) (29) . This is consistent with the predominance of a p37 form of StAR (13) or retention of intermediate forms, which occur when CCCP, a powerful respiratory uncoupler, prevents entry into the matrix (30) . Inhibition of cholesterol metabolism by o-phenanthroline (o-phen), an inhibitor of mitochondrial proteolysis, and by CCCP (13, 30) suggests that this cleavage of StAR is necessary for cholesterol transfer. In isolated mitochondria, cholesterol metabolism, mediated by recombinant StAR, is blocked by CCCP and by inhibition of ATP turnover, each consistent with a need for StAR processing (31) . However, the activity of StAR without the targeting sequence in COS-1 cells has led to a broad acceptance that StAR functions on the outer membrane and is than removed from the active site by intramitochondrial transfer (20, 30) .
In a previous study (32) , we showed that ACTH maximally stimulated steroid synthesis in rats in vivo within 10 min, without any measurable change in multiple forms of total StAR. In this paper, we address the question of whether mitochondrial processing is, indeed, essential for activated adrenal cholesterol metabolism, despite the evident possibility of extramitochondrial StAR activity. Here, we resolve why changes in cholesterol metabolism appear to occur without measurable changes in the multiple forms of immunodetectable StAR. We show that these paradoxes are explained by the dependence of activity exclusively on newly synthesized StAR and by the need for extraordinarily little intramitochondrial StAR for maximum activity. The basis for differences between these adrenal studies and experiments with recombinant StAR are discussed.
MATERIALS AND METHODS
Animal Treatment-Female Sprague-Dawley rats (175-200 g) were obtained from Harlan Sprague-Dawley (Madison, WI). All animal treatments were performed at 10:00 a.m. Rats were housed in a stressminimizing environment. Rats were given multiple injections of ACTH (1-24 fragment) (Sigma) every 30 min during a period of 3 h. A group of rats was injected with CHX (Sigma) (20 mg/rat) 20 min prior to sacrifice, in addition to ACTH treatment. Animals were sacrificed by decapitation, blood was collected to measure steroids, and adrenals were surgically removed, defatted, and rapidly homogenized in TRIzol reagent (Life Technologies, Inc.; 50 -100 mg of tissue/1 ml of reagent) for protein and RNA analysis.
Preparation of Polyclonal Antiserum to StAR-Antibody was elicited to the full-length mature form of StAR. The StAR cDNA (18) was digested with SmaI and ligated to BamHI linkers. The DNA was digested with BamHI, and the 1273-base pair fragment was cloned into the dephosphorylated BamHI site of GEX2T (Amersham Pharmacia FIG. 1. Corticosterone level in plasma and StAR expression in adrenal glands from rats treated with ACTH and CHX. A, plasma corticosterone levels following treatment with ACTH or ACTH and CHX for the last 20 min. B and C, two-dimensional Western immunoblot analysis of StAR isolated from the adrenals of these rats. Rats, housed in stress minimizing conditions, were injected with 0.2 mg (about 3 units) of ACTH for 3 h. A second group of rats was also injected with CHX (20 mg/rat) 20 min before decapitation. Corticosterone was extracted from blood plasma and analyzed by HPLC. Error bars represent the mean Ϯ S.D. for the values obtained from three rats for each treatment. Total adrenal protein from the same rats was separated by two-dimensional gel electrophoresis and immunoblotted with StAR anti-peptide antibody (B) and with anti-recombinant StAR polyclonal antibody (C). The pI values of two StAR isoforms are indicated. Equal protein loading was verified by immunoblotting the same membrane with ␣-actin antibody (not shown).
FIG. 2.
35 S labeling and immunoblotting of StAR in primary rat adrenal cells. Effect of the mitochondrial protease inhibitor o-phen. A, the effect of BrcAMP and o-phen on total StAR expression, as determined by two-dimensional immunoblotting with the polyclonal StAR antibody. B, the formation of StAR isoforms within the 30-min treatment periods, determined by autoradiography of 35 S-labeled proteins. Primary cells (2 ϫ 10 6 ), obtained from zona fasciculata of rat adrenal glands, were incubated with 1 mM 8-Br-cAMP and 1 mCi of [ 35 S]methionine for 30 min (a second group of cells was unlabeled) with or without 2 mM o-phen. 200 g of protein was loaded on each gel to separate proteins by two-dimensional gel electrophoresis. Gels were dried, and radiolabeled proteins were visualized by autoradiography. Proteins from the other set of gels were transferred to the nitrocellulose membrane and immunoblotted. Biotech). The linker sequences (5Ј-CGCGGATCCGCG-3Ј) were added to maintain the reading frame and add an alanine residue between the thrombin cleavage site of the vector and amino acid 46 of StAR. This removes all but two amino acid residues of the predicted signal peptide, resulting in a fusion of the mature 30-kDa form of StAR with GST. The protein was expressed in bacteria, purified by glutathione affinity chromatography, and injected into rabbits. A specific, high titer antibody was elicited that was suitable for immunoprecipitation and Western blot analysis.
Cell Culture and Cell Treatments-Rat adrenal cells were isolated from inner cortex zone of adrenals (fasciculata cells) that were obtained fresh from Harlan Bioproducts (Madison, WI), subjected to collagenase A (Roche Molecular Biochemicals) digestion, and cultured for 24 -48 h as described previously (33) . Cell treatment and labeling were performed in Krebs buffer containing 0.2% glucose and 0.1% bovine serum albumin for 30 min at 37°C. Cells (2 ϫ 10 6 ) were labeled with 1 mCi of [ 35 S]methionine (EXPRE 35 S 35 S labeling kit; PerkinElmer Life Sciences). Cells were washed three times with Krebs buffer, scraped from the plates, and pelleted. Cell pellets were used for 35 S-protein gel electrophoresis analysis.
Y-1 cells (mouse tumor adrenal cells) were obtained from American Type Culture Collection (Manassas, VA) and maintained in Ham's F-10 (Sigma) supplemented with 15% horse serum (Atlanta Biological, Norcross, GA), 2.5% fetal bovine serum (Hi-Clone, Logan, UT), penicillin (50 units/ml; Sigma), and streptomycin (50 mg/ml; Sigma). All cell treatments were performed in six-well plates with 1-2 ϫ 10 6 cells/well in serum-free medium. In some experiments, cells were prelabeled for 5 min with [ 35 S]methionine (0.4 mCi/ml) in methionine-free Dulbecco's modified Eagle's media. Cells were typically stimulated with 8-BrcAMP, as designated. Cell medium was collected after each treatment to measure pregnenolone. Determination of Plasma Corticosterone-Steroids were extracted from plasma with ethyl acetate-acetone (2:1). Cortisone was used during extraction as an internal standard. The organic phase was then evaporated under nitrogen with heating at 37°C. The residue was dissolved in 100 l of the methanol and subjected to HPLC analysis using a reverse-phase C18 column (Beckman, 5 m, 4.6 mm ϫ 25 cm) with a linear gradient of methanol (50 -100%). Detection was carried out at 254 nm by a Beckman System Gold programmable Detector Module 166, and the data were analyzed by System Gold Software via a Beckman System Gold Analog Interface Module 406.
Pregnenolone Formation-Cell medium was collected after each treatment and assayed for pregnenolone by RIA. 10 M trilostane (a gift from Dr. R. J. Harmon (University of Kentucky)) and 20 M SU-10603 (CIBA-GEIGY Corp., Summit, NJ) were added before each treatment to block further pregnenolone metabolism. Since pregnenolone is rapidly removed in the absence of these inhibitors, pregnenolone formation reflects only metabolism after the addition of these inhibitors. Pregnenolone was extracted from cell media with hexane. The organic phase was then evaporated under nitrogen with heating at 37°C. The residue was reconstituted in RIA buffer, and RIA was performed as described before (34) 35 S-StAR expression was quantitated from the intensities of the bands in B using laserscanning densitometry. Results are expressed as intensities in arbitrary integration units that apply to both p37 and p30 bands. The zero time expression levels, where treatments were identical, have been averaged for both p37 and p30. One of two sets of experiments is represented here. For p37, the differences in control (C), o-phen, or CCCP treatments between individual cultures were within the experimental variability and are presented as a single dotted line.
In phase 1, cells were incubated with 1 mM 8-Br-cAMP (Roche Molecular Biochemicals) with or without one of the following: 2 mM o-phen, 20 M CCCP, and 0.2 mM CHX (all of the inhibitors were obtained from Sigma). Each phase 1 incubation was carried out at 37°C for 5-15 min as specified. Medium was collected for pregnenolone measurement. Cells then were washed with 10°C medium (without inhibitors or Br-cAMP), and new medium was added also without Br-cAMP but with the inclusion of CHX. This incubation was carried out for 15 min at 37°C (phase 2). Again, medium was collected to determine the level of generated pregnenolone.
Two-dimensional Gel Electrophoresis-The pelleted cells were lysed in osmotic lysis buffer (10 mM Tris, pH 7.4, 0.3% SDS, 50 g/ml RNase, and 100 g/ml DNase in 5 mM MgCl 2 , 1% protease inhibitor mixture (Sigma)). The samples were then boiled with SDS boiling buffer (5% SDS, 10% glycerol, and 60 mM Tris, pH 6.8). Aliquots of the samples were removed for protein determination and trichloroacetic acid precipitation for protein-bound 35 S counts. The rest of the material was lyophilized and dissolved in SDS-boiling buffer with 5% ␤-mercaptoethanol to a protein concentration of 5 mg/ml. Two-dimensional electrophoresis was performed using isoelectric focusing followed by SDS-PAGE (10% acrylamide) as described previously (32) . Protein (200 g) was loaded on each tube gel for isoelectric focusing. For experiments that required immunoblotting after electrophoresis, the proteins were transferred to the nitrocellulose membrane. The position of the molecular weight markers was determined by staining the membrane with Ponceau S. Western immunoblot analysis (35) was completed, using a rabbit antibody (1:6000) raised against a peptide sequence of mouse StAR, kindly provided by Drs. N. Boujrad and V. Papadopoulos (Georgetown University, Washington, D. C.) and using polyclonal ␣-StAR antibody, followed by the secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (Promega, Madison, WI). Proteins were visualized by exposing the nitrocellulose membranes following treatment with the ECL detection reagent (Amersham Pharmacia Biotech) to the ECL x-ray film (Amersham Pharmacia Biotech).
To perform fluorography following second dimension separation, the gels were fixed overnight in 50% methanol, 10% acetic acid; rehydrated in 10% acetic acid; dried onto filter paper; and exposed to x-ray film.
14 C molecular weight markers (Diversified Biotechnology, Newton Center, MA) were loaded on the basic edge of each gel.
Immunoprecipitation of StAR-Y-1 cells were labeled with [ 35 S]methionine (0.4 mCi/ml) in methionine-free Dulbecco's modified Eagle's medium with or without 1 mM Br-cAMP, 20 M CCCP, and 2 mM o-phen (phase 1). After washing the cells, the radioactive media was replaced with serum-free culture media containing 0.2 mM CHX. Incubation was continued for 15 or 35 min (phase 2). Then cells were rinsed with phosphate-buffered saline and scraped into 0.6 ml of ice-cold immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1% Nonidet P-40, 0.25% deoxycholate, 0.05% SDS, 40 mM NaF, 10 mM NaMo, 1 mM phenylmethylsulfonyl fluoride, 1% protease inhibitor mixture (Sigma)). Cell lysates were repeatedly passed through a 23-gauge needle and centrifuged at 12,000 ϫ g for 5 min in an Eppendorf centrifuge. Equal aliquots of protein from each supernatant were first incubated with 20 l of protein A-agarose plus (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) to eliminate nonspecifically bound proteins for 30 min at 4°C. After centrifugation, supernatants were incubated with 1 l of StAR antibody overnight at 4°C and then for 3 h with 100 l of agarose A. Immunocomplexes were washed several times with immunoprecipitation buffer and collected by centrifugation. The final pellets were resuspended in sample buffer, and equal amounts of counts were loaded on SDS-PAGE 10% gels. Gels were fixed for 30 min in 50% methanol, 10% acetic acid fixation solution, soaked for 15 min in Amplify (Amersham Pharmacia Biotech), dried for 90 min at 65°C, and exposed to Kodak BioMax film (Eastman Kodak Co.).
Quantitative analysis of StAR expression was completed by soft laser-scanning densitometry employing a Zeineh model SL-504-XL soft laser-scanning densitometer (Fullerton, CA).
Protein Determination-Protein was measured using the BCA method (Pierce) according to the manufacturer's instructions.
RESULTS

Expression of Total StAR Does Not
Correlate with Steroidogenesis-In previous work, we have detected multiple forms of StAR in rat adrenals in vivo (32) . CHX (protein synthesis inhibitor) rapidly inhibits steroidogenesis in vivo by limiting access of cholesterol to P450scc (4, 36) . Here, we have tested whether changes in StAR correlate with this inhibition. Fig. 1 shows that a 3-h stimulation of female rats by ACTH produces a 4-fold increase in the level of blood corticosterone. Injection of the CHX in the last 20 min of the ACTH treatment lowered blood corticosterone below unstimulated levels. This indicates a rapid and full block of corticosterone secretion within this period. Based on our recent work, a 20-min ACTH stimulation, which is sufficient for the peak of corticosterone levels, did not elevate immunodetectable StAR isoforms (32) . Analysis of this 3-h ACTH stimulation with a StAR anti-peptide antibody (Fig. 1B) re- vealed four StAR forms. Two forms that were observable in unstimulated rats were relatively insensitive to this ACTH treatment. Two additional forms that exhibit more acidic pI values (Ͻ6.5) were only evident after this hormonal stimulation. These forms with the more acidic pI values were exactly compatible with previously described phosphorylated forms (13) .
This complete inhibition of corticosterone formation by CHX takes place without an affect on any of StAR forms. The lack of correlation of StAR with this activity change remained even when analyzed with a much more sensitive antibody raised against recombinant StAR, which detected at least four additional forms (Fig. 1C) . We conclude that none of these eight detectable StAR forms is either particularly labile or responsible for the rapid loss of steroidogenesis produced by CHX. Like the results with acute ACTH stimulation in vivo, this suggests that total immunodetectable StAR is not a good indicator of StAR activity.
Previous work has shown that processing of p37 StAR to mature p30 forms is blocked by o-phen, an inhibitor of mitochondrial proteolysis (13, 30) . In view of the controversy concerning the role of StAR processing in cholesterol metabolism, we measured the changes in immunodetectable StAR forms in relation to effects of o-phen on cholesterol metabolism. Primary cells, which were isolated from rat adrenals and cultured up to 48 h, were stimulated with Br-cAMP in the presence of o-phen. Pregnenolone production was stimulated 4-fold (from 2 to 8.0 ng/15 min/10 6 cells), and this increase was, indeed, completely blocked by o-phen (2.0 ng/15 min/10 6 cells). Two-dimensional immunoblots with ␣-StAR antibody ( Fig. 2A) showed approximately equal levels of a set of four major spots, in pairs corresponding closely to the pI values previously seen for unphosphorylated forms (1 and 2) and more acidic phosphorylated StAR forms (3 and 4). The separation of major and additional minor spots was highly reproducible but failed to detect changes in any of StAR isoforms in response to either Br-cAMP or o-phen. (Fig. 2A) . This experiment further establishes that expression of total levels of individual forms of StAR is a poor indicator of activity.
Activation of Steroidogenesis Parallels Synthesis of New
StAR following Acute cAMP Stimulation-As an alternative mechanism, we have tested the possibility that only newly synthesized StAR determines cholesterol transfer to P450scc (13) . This is necessarily blocked by CHX and also should be sensitive to the processing inhibitor, o-phen. In parallel with the above immunodetection analysis, a second set of primary cells were stimulated with 8-Br-cAMP for 30 min and labeled concurrently with [ 35 S]methionine. This brief labeling time preferentially detects incorporation of 35 S into more the labile proteins. Fig. 2B shows that Br-cAMP decreased 35 S-labeling of two more basic isoforms (1 and 2) in parallel with appearance of two more acidic 30-kDa proteins (3 and 4) . These changes and the relative location of acidic spots correspond closely to the previously reported generation of phosphorylated forms (13, 37) . o-Phenanthroline treatment blocked the acute formation of 35 S-labeled p30 and p32 proteins. An additional p37 protein was detectable in the expected location for the StAR precursor but only in the presence of o-phen (Fig. 2B, white  arrowhead) . The failure of 35 S labeling in control cells to detect acidic StAR forms that are strongly represented in the equivalent immunoblots could result from a slow accumulation of these forms under basal culture conditions. A 32-kDa protein (Fig. 2B, 5) , which was largely insensitive to Br-cAMP treatment, was also removed by o-phen. No equivalent form was seen in the immunoblots, thus raising doubts about whether this was a StAR isoform.
This correlation between disappearance of 35 S-StAR forms and loss of stimulated cholesterol metabolism after o-phen treatment and the insensitivity of immunodetectable forms suggests that only newly synthesized and processed StAR mediates cholesterol access to P450scc. The levels of preexisting StAR are evidently too high to allow detection of changes in small amounts of synthesized StAR by immunoblotting. This lack of change in StAR immunoblots also shows that various forms of immunodetectable StAR turn over very little in this 30-min incubation period. ]methionine, prior to Br-cAMP treatment, followed by immunoprecipitation of StAR. After this 5-min labeling period, we were able to detect p37 at a much higher level than p30 (Fig. 3B) . After a further 7.5 min, the labeling of p37 in control cells doubled to a steady state level, which was maintained in the next 7.5-min period. By contrast, the p30 band in control cells, which was nearly absent after the 5 min, increased linearly in each subsequent 7.5-min period. This labeling sequence indicates that the p37 form is indeed a precursor of the p30 form. The labeling of the p30 form in each of these 7.5-min periods was about equal to the rate of labeling of the p37 form in the initial period, which is consistent with a rapid and nearly complete turnover of p37 to p30. The time to steady state is typically determined by the first order degradation, suggesting that the approximate t1 ⁄2 for processing of p37 is 5 min. By contrast, p30 evidently requires much longer, reaching a steady state (t1 ⁄2 Ͼ 20 min). These considerations indicate that 35 S labeling of StAR for 20 min necessarily greatly underrepresents the proportion of p30 forms relative to p37.
Br-cAMP did not increase the labeling of p37 relative to p30 after 7.5 min of treatment (Fig. 3B) , but this and two other experiments (Figs. 8 and 9 ) suggest a 2-fold increase in this ratio after 15 min. There was no effect of Br-cAMP on p30 formation after either 7.5 or 15 min, indicating that Br-cAMP does not increase the processing rate. StAR mRNA levels do not change in this period; therefore, this small increase in p37 most likely reflects a Br-cAMP-induced increase in translation. Fig.  3 , additionally, shows that o-phen and CCCP prevent formation of p30 although without a substantially increased level of p37. Neither agent affected total 35 S-protein synthesis during this short time of treatment (data not shown).
Immunoblots, generated under similar conditions (Fig. 4A) , indicate that Y-1 cells synthesize StAR at a linear rate between 30 and 180 min after Br-cAMP addition, while there is a reproducible 2-fold decrease in the initial 15-30 min (consistent in three experiments). This linear formation appears to proceed after a delay that is consistent with the new synthesis shown by 35 S labeling in Fig. 3B . The linear rate of total StAR synthesis (standardized with recombinant GST-StAR; 53 kDa) was 1 fmol/min/10 6 cells (Fig. 4C) . This overestimates the pp30, generated 10 min after Br-cAMP stimulation, since p30 formation is not linear from zero time. There is a delay caused by p37 processing that precedes p30 formation (Fig. 3) . The maximum rate of stimulation of cholesterol metabolism in this batch of cells was 2.0 ng/10 6 cells/15 min (0.42 pmol/min/10 6 cells). This demonstrates a stoichiometry of at least 400 cholesterol molecules transported and metabolized/min/newly synthesized StAR molecule.
Processing Inhibitors Affect Cholesterol Transfer-We have also measured the metabolism of 20␣-hydroxycholesterol (20␣-HOC) that, like other hydroxycholesterol analogs, reacts at P450scc without the constraints on membrane transfer that apply to cholesterol (5) . Fig. 5 shows that o-phen and CCCP did not inhibit turnover of 20␣-HOC, at concentrations that maximally inhibit acute stimulation of cholesterol metabolism. Substantially longer exposures appear to compromise this activity through more general effects on cell function. The absence of an effect of CCCP, which is a potent and effective uncoupler of the mitochondrial respiration, additionally indicates that this process is not directly linked to P450scc turnover. These inhibitors, therefore, selectively block cholesterol metabolism, which is consistent with the involvement of StAR processing in cholesterol transport to P450scc.
Br-cAMP and o-Phenanthroline Generate Active Intermediates That Sustain Cholesterol Metabolism in Y-1 and Primary
Adrenal Cells-We have developed a two-phase assay, which measures the activity of StAR precursors that accumulate when the processing is inhibited (Fig. 6A) . In phase 1 of this assay, adrenal cells were stimulated by Br-cAMP for varying lengths of time (5-15 min), either with or without a processing inhibitor. Then cells were washed with 10°C media to stop this activation and to remove both the stimulant and the inhibitor. In a subsequent second step (phase 2), CHX was added to prevent any further protein synthesis, and the stimulant was omitted. In both phases, further metabolism of pregnenolone was inhibited by the addition of trilostane. Pregnenolone formation in phase 2 then measures the capacity of the accumulated mediators to sustain the metabolism of available cholesterol. was completely inhibited by CHX and by the two processing inhibitors (o-phen and CCCP), whereas basal activity was unaffected (data not shown). In phase 2, cells retained cholesterol metabolism at the normal stimulated level in the absence of Br-cAMP and further protein synthesis. This high phase 2 activity was unexpected, since in vivo and in rat adrenal cell suspensions, CHX rapidly reverses ACTH or cAMP stimulation (10) . This activity demonstrates the synthesis and activation by Br-cAMP in phase 1 of a relatively stable protein mediator that requires mitochondrial processing for activity. This is fully consistent with formation of p37 StAR and conversion to an active pp30 form. The addition of Br-cAMP in phase 2 did not affect pregnenolone formation (data not shown). This indicates that activation of early steps in cholesterol transfer, such as cholesterol ester hydrolysis (4, 7-8), do not further contribute to the phase 2 activity.
While o-phen or CCCP inhibited Br-cAMP stimulated phase 1 activity, their removal led to recovery of most of the activated cholesterol metabolism in phase 2 (Fig. 6B) . This establishes that these inhibitors indeed permit formation of a precursor, such as phosphorylated p37 StAR that can only effectively mediate this phase 2 metabolism when processing is restored.
An equivalent set of two-phase experiments was carried out in primary rat adrenal cells. These cells were more active than Y-1 cells but exhibited a very similar time course for the stimulated cholesterol metabolism. Again, stimulation by Br-cAMP in phase 1 was fully sustained in phase 2 after removal of the stimulus and in the presence of CHX (Fig. 6C) . o-Phenanthroline was similarly effective in inhibiting phase 1 metabolism. When o-phen was removed under phase 2 conditions, activity was restored to 75% of the maximum level, despite removal of the stimulus.
Generation of a Phase 2 Mediator Precedes the Increase of Cholesterol Metabolism in Phase 1-
The stimulated rate of steroidogenesis in the first 5 min of phase 1 was over 10 times lower than in the next 10 min (Fig. 7) . Nevertheless, this 5-min period was sufficient to generate mediators that provided 60% of maximum activity in phase 2. The presence of o-phen in this shortened phase 1 now permitted nearly complete recovery of the activity in phase 2. This confirms that an activator is substantially formed before increased cholesterol metabolism, even when processing is inhibited. This delay in cholesterol metabolism is completely consistent with the kinetics of generation of newly synthesized p37 and p30 StAR that is shown in Fig. 3 . 35 Slabeled StAR were used to analyze the conversion of newly formed p37 to p30 during this phase 2 cholesterol metabolism. Fig. 8 shows the various 35 S-StAR forms, resolved after immunoprecipitation at the end of phase 1 (0 min) and after 15 and 35 min of further incubation in phase 2, respectively. In phase 2, in Br-cAMP-stimulated cells, 80 -90% of 35 S-p37 mostly converted to 35 S-p30 within 15 min, and the conversion was completed in 35 min (Fig. 8, B and C) . This conversion was less complete after 15 min, when o-phen was present in phase 1. o-Phenanthroline may not be removed completely or, alternatively, mitochondrial proteolytic function may not be fully restored because of metal ion depletion by o-phen.
S-p37 StAR Is Converted to S-p30 in Phase 2 Prior to the Loss of Activated Cholesterol Metabolism-Changes in
Previous work has led to the suggestion that p37 directly mediates cholesterol transfer (38) . This experiment clearly separates a decline in p37 levels from a loss of activated cholesterol metabolism. The rate of pregnenolone formation falls much more slowly (t1 ⁄2 ϳ7.5 min) (Fig. 8C ) than this loss of p37 (t1 ⁄2 ϳ5 min). This establishes that this form is not the major mediator of cholesterol transfer in these cells.
This conversion of 35 S-p37 StAR to 35 S-p30 was slowed, but not stopped, by the addition of o-phen or CCCP during the phase 2 incubation (Fig. 9, B and C) . During this 15 min, o-phen, but not CCCP, prevented the loss of p37. Instead, the inhibition by CCCP resulted in a predominance of intermediate StAR cleavage products (p35 and p32). The same trends were seen when the experiments were carried out either with or without the addition of o-phen in phase 1. However, when o-phen was originally present in phase 1, the starting proportion of p37 was substantially elevated at the expense of p30 (Fig. 9C) . According to studies in yeast, CCCP blocks processing by preventing uptake of the precursor through the inner membrane channel (39) . This conversion of p37 to intermediate forms in the presence of CCCP suggests that o-phen-sensitive cleavages to p35 and p32 occur prior to their transfer through the inner membrane. (Fig. 9D) . This supports our previous conclusions from the data of Fig. 7 that sufficient active p30 StAR has been generated in phase 1 to sustain cholesterol metabolism. By contrast, when o-phen was present in phase 1, the cAMP elevation of phase 2 activity was then almost completely attenuated by either o-phen or CCCP down to the phase 2 activity generated from unstimulated cells. This parallels the effects of these inhibitors on StAR processing during phase 2 (Fig. 9, B and C) . Thus, continued processing remains necessary for optimal cholesterol metabolism only when processing is inhibited in phase 1. This phase 2 sensitivity, then, is consistent with cholesterol metabolism, maintained by processing of p37 or precursors that accumulate in phase 1.
The Generation of Mediators as Assessed by Inhibition of StAR Synthesis and Processing-
We have used CHX and processing inhibitors to characterize better the generation of mediators during phase 1 of cholesterol transfer activation. The addition of CHX at the time of cAMP stimulation completely prevents the activation of cholesterol metabolism measured at the end of the 15-min phase 1 period (Figs. 6 and 10) , whereas there was no inhibition when CHX was added after 15 min of stimulation (typical phase 2). Since CHX very rapidly (within ϳ1 min) stops protein synthesis in Y-1 cells (Fig. 10A) , the addition of CHX at later times will track the levels of StAR mediators formed at these times. Fig. 10 shows that the activation retained at 15 min increases linearly with the extent of this delay in the addition of CHX and also that the time lag is short.
We also measured the impact of delayed addition of the processing inhibitors on cholesterol metabolism within 15 min. The use of processing inhibitors shows the same transition from complete inhibition to resistance over the course of 15 min. The effects of CCCP and o-phen differ from CHX in that there are marked delays for generation of StAR mediators that are sensitive to each of these inhibitors. These time lags are paralleled in the stimulation of cholesterol metabolism and also the formation of newly synthesized p30 StAR forms (Fig. 3) . These time courses are consistent with the different sensitivity of the intermediate forms of StAR to these inhibitors. CHX allows p37 and all intermediates, formed at the time of addition, to proceed to pp30, whereas CCCP stops the conversion of all precursor forms to pp30. o-Phenanthroline prevents progression of p37 but is less effective in blocking intermediate forms. The 5-min lag, seen for CCCP and o-phen, indicates near exclusive formation of p37 in the initial 5 min, which would be converted to pp30 after the addition of CHX. Differences between o-phen and CCCP at later time points can be attributed to the appreciable levels of intermediate forms (p32 and p35) that are much less sensitive to o-phen.
DISCUSSION
Recent experiments using recombinant StAR have led to the concept that StAR acts primarily on the outer membrane of the adrenal mitochondria and that processing is merely involved in the clearance of StAR (20) . The work presented here shows that, despite this extramitochondrial capability, hormonal stimulation of cholesterol metabolism in adrenal cells requires intramitochondrial processing of the 37-kDa StAR precursor and that targeting of the mature phosphorylated form, pp30, to the inner mitochondria provides a highly efficient cholesterol transfer mechanism. This mechanism allows activation of cholesterol transfer with remarkably little StAR (10 fmol/10 6 cells of new StAR after 10 min), which functions with high activity (over 400 molecules of cholesterol/StAR/min).
We also show here, that newly synthesized and processed pp30 StAR is essential for this cholesterol transfer process, whereas even substantial amounts of mitochondrial StAR formed prior to stimulation are inactive. Full activation and inhibition of cholesterol metabolism in adrenal cells, both in vitro and in vivo, occurred without detectable changes in immunodetectable StAR forms, even when their levels were substantial (Ref. 32 ; Figs. 1 and 2) . By contrast, the time course for activation of the cholesterol metabolism and the effects of inhibitors of StAR synthesis each indicate a close correlation between the rate of cholesterol metabolism and the amount of newly synthesized pp30, as measured by 35 S labeling of StAR immunoprecipitates (Fig. 3) . Thus, the long established effectiveness of protein synthesis inhibitors in blocking cholesterol metabolism (as in Fig. 1 ) could be attributed to this requirement for new synthesis. Similarly, the parallel inhibitory effects of o-phen and CCCP on pregnenolone synthesis and p30 formation indicate a requirement for processing of this newly synthesized StAR. Nevertheless, activation of cholesterol metabolism in Y-1 cells becomes independent of these processing inhibitors within 15 min (Fig. 9D) when sufficient pp30 has formed to sustain cholesterol transfer (Fig. 3) . This eventual resistance to o-phen and CCCP and the insensitivity of metabolism of 20␣-hydroxycholesterol to these inhibitors (Fig. 5 ) each confirm that both the membrane disposition of cholesterol and direct turnover of P450scc are completely unaffected by these processing inhibitors.
The major observable effect of Br-cAMP on StAR function within the activation period is on the extent of phosphorylation of StAR rather than subsequent steps. However, clearly other steps mediating mitochondrial cholesterol transfer may be affected. Br-cAMP activates phosphorylation of the majority of p30 StAR in adrenal cells (Fig. 2) but has little impact on the initial translation or processing rates during the 10 -15 min needed for the attainment of maximum cholesterol metabolism (Fig. 3) . The analysis of newly formed ( 35 S-labeled) and preexisting immunodetectable p30 StAR forms indicates that similar phosphorylated forms exist in both pools ( Figs. 1 and 2 ). There was no evidence for a rapidly generated labile p30 StAR form that might account for the rapid changes in cholesterol metabolism. Indeed, total StAR appears to decline somewhat during the initial 15 min after the addition of Br-cAMP. The StAR contribution to cholesterol transfer must, therefore, come from the very small amount of phosphorylated p30 (pp30) that is generated within this 5-10-min activation period that is insufficient to cause a measurable increase relative to the initial nonfunctional levels. Maximum rates of cholesterol metabolism are reached before any of the substantial rise in StAR mRNA and new protein synthesis. Other factors apparently prevent further increases in the rate of cholesterol metabolism during the subsequent 10-fold elevation of StAR expression (Fig. 4) .
The relative rates of formation and turnover of immunoprecipitated 35 S-StAR forms show that the rapid attainment of a steady state level of p37 (Fig. 3) is due to nearly quantitative conversion to p30 forms with a t1 ⁄2 of about 5 min (Fig. 8) . The time required to achieve a maximum rate of metabolism is close to the time necessary to achieve a steady state of newly synthesized p37 (5-10 min), which is mostly phosphorylated based on the predominance of the pp30 cleavage products (Fig. 2) . During this early period of generation of pp30 from pp37, cholesterol metabolism is much more sensitive to o-phen and CCCP than CHX (Fig. 10) . The insensitivity to these inhibitors 10 min after cAMP stimulation (Fig. 9D) indicates that even the very little pp30 formed at this time is sufficient to sustain cholesterol transfer. This steady state level for p37, therefore, corresponds to a maximum rate of formation of pp30. Surprisingly, there is relatively little accumulation of p37 StAR when processing is inhibited (Figs. 3, 8, and 9 ), although this represents by far the predominant turnover route. Possibly, this steady state level of p37 is close to the capacity of the uptake receptor and import channel (40) . Any further accumulation would then lead to increased proteolysis of p37 by cytosolic proteases.
The absence of changes in any of the multiple immunodetectable forms of p30 StAR during 20 -30-min exposures to indicates that these forms turn over relatively slowly both in vivo and in vitro (t1 ⁄2 Ͼ1 h). Paradoxically, in Y-1 cells, Br-cAMP initially stimulates removal of some of the preexisting StAR even while increasing new synthesis (Fig. 4) . These opposing processes may contribute to the difficulties in measuring early cAMP-induced increases in total StAR.
We have used a novel two-step assay to show that in adrenal cells Br-cAMP stimulates the synthesis of protein mediators that then sustain near maximum levels of cholesterol metabolism without further synthesis (Fig. 6 ). The characteristics of this two-step mediation of cholesterol metabolism correspond to the formation of p37 StAR as a precursor that then generates pp30 as the active agent. Thus, Br-cAMP rapidly generates optimal amounts of this protein mediator within 5-10 min that then maintains cholesterol metabolism without further need for this stimulus, protein synthesis, or processing. Thus, phase 2 cholesterol metabolism becomes completely insensitive to CHX, o-phen, and CCCP. This is consistent with the involvement of highly active newly synthesized intramitochondrial pp30. In this way, we have separated formation of a measurable amount of new StAR (10 fmol/10 6 cells at the end of phase 1) from the capacity to move cholesterol to P450scc at an increased rate (0.4 pmol/min/10 6 cells in phase 2). Although processing inhibitors (o-phen or CCCP) inhibit activation of cholesterol metabolism, we demonstrate a restoration of a similarly sustainable cholesterol metabolism after the removal of these inhibitors by washing. This restoration of cholesterol metabolism increases to the extent that p37 and partially processed forms (p35 and p32) are subsequently converted to p30 and is fully inhibited by both processing inhibitors. CCCP is effective in blocking this restoration despite allowing conversion of p37 to p35 and p32 intermediate forms (Fig. 9 ). This effectiveness of CCCP establishes that p35 and p32, which are probably partially transferred into the intermembrane space, are also ineffective in mediating cholesterol transfer. StAR processing is equally important to cholesterol metabolism in testis MA-10 cells. Exactly the same sensitivity to o-phen and CCCP is seen during 30 min of cAMP stimulation of MA-10 cells, and phase 2 activity is, again, sustained in the absence of continued stimulation. 2 However, the inclusion of o-phen in phase 1 completely prevented phase 2 activity in MA-10 cells. This failure of the cAMP/o-phen combination to generate phase 2 activity in MA-10 cells paralleled a much lower accumulation of p37. This is consistent with a need for p37 to sustain phase 2 activity after the removal of o-phen. This difference is remarkable, considering that phase 2 activity after o-phen inhibition was invariably seen in Y-1 cells of widely differing activities and also in primary adrenal cells. Degradation of p37 appears to be a more effective reaction in MA-10 cells. Fig. 8C illustrates the much slower decline in cholesterol metabolism in Y-1 cells after the removal of Br-cAMP (t1 ⁄2 ϳ7.5 min) compared with the rapid loss of p37 (t1 ⁄2 ϳ5 min). This is also consistent with pp30 rather than p37 as the direct mediator. However, pp30 is probably only active with respect to intermembrane transfer while inserted in the inner mitochondrial membrane. This newly formed pp30 should then become ineffective when translocated to the matrix vesicles, which provide the major location for StAR (42) . The much more rapid inactivation of cholesterol metabolism, in vivo ( Fig. 1 ) and in adrenal cell suspensions (9, 10) , following inhibition of protein synthesis, may result from this matrix relocation. We suggest that a more rapid matrix translocation of pp30 is necessitated by the higher cholesterol flux in the more active normal adrenal cells. The matrix vesicles also contain much of the P450scc, thus raising the possibility that StAR may play an additional role in maintaining the accessibility of cholesterol for metabolism at this location. Fig. 11 summarizes the several steps involved in the processing of p37, including the sites of action of the processing inhibitors. This representation is fully consistent with the mechanism proposed by Orme-Johnson and co-workers (13) (14) (15) , in which the p37 precursor is phosphorylated during or immediately after translation, and with previous models for mitochondrial processing (27, 28, 42) . A series of papers by King et al. (31, 54) has further defined this mechanism by showing that a mitochondrial membrane potential and ATP turnover are essential for StAR activity, whereas a proton gradient is not essential. This is, again, fully consistent with the generation of pp30 within the inner mitochondria as the requirement for activity.
Factors other than StAR clearly play a major role in limiting these cellular steroidogenesis rates. Thus, the maximum rate of cholesterol metabolism is achieved in primary and Y-1 adrenal cells prior to a 10-fold rise in mRNA and protein trans-2 I. P. Artemenko, unpublished results. FIG. 11 . Summary of the proposed changes in StAR in adrenal mitochondria following cAMP stimulation. p37 is substantially phosphorylated to pp37, based on the formation of pp30 rather than p30 (Fig. 2) , but this does not affect mitochondrial transfer or processing (Fig.  3) . pp37 binds to outer membrane docking sites and is then transferred, leading with the N terminus through an outer membrane channel. Intermediate forms, pp35 and pp32, are formed by proteolysis that predominantly occurs in the intermembrane space. This is based on the loss of pp37 and the accumulation of these intermediates with CCCP, which blocks transfer through the inner membrane channel. pp37 and pp35 each accumulate with o-phen treatment (Fig. 9) , indicating that this agent inhibits proteolytic conversions of pp37 to pp35 and to pp32. pp30 is generated by a final proteolysis in the matrix. pp30 initially binds the inner membrane via the C terminus and then relocates to matrix vesicles. lation. 3 We have previously shown that rates of pregnenolone formation in stimulated bovine adrenal cells are determined by the rate of cholesterol movement to the mitochondria (36) . Differences in lipoprotein uptake, lysosomal processing, ester hydrolysis, and outer membrane uptake may limit transfer of cholesterol to the mitochondria (44) . Recently, in cytosol of stimulated adrenals, phosphoprotein p43 was identified to act as an intermediary in the stimulation of steroid synthesis through arachidonic acid release and has been found to be a member of the acyl-CoA thioesterase family (45, 46) . The function of StAR is also likely augmented by the peripheral benzodiazepine receptor, which associates in the adrenal mitochondrial outer membrane with porins after ligand activation. This complex organizes a pool of cholesterol that may be essential for subsequent StAR-mediated transfer (47) (48) (49) (50) (51) .
The lack of a requirement for mitochondrial uptake of recombinant StAR for steroidogenic activity in COS-1 cells is probably due to a low intrinsic membrane specificity for StAR in mediating cholesterol exchange (20, 52) . Thus, StAR facilitates cholesterol exchange even between artificial phospholipid membranes (41) . We have confirmed the effectiveness of StAR in the absence of a targeting sequence but also have found that under these conditions cholesterol metabolism is not limited by the amount of StAR. 4 These experiments with COS-1 cells and equivalent experiments with isolated mitochondria (20, 52) require relatively high amounts of StAR. Nevertheless, each of these activities requires the conserved C-terminal lipid-binding domain that is essential for adrenal function (21, 22, 53) . We suggest that, in adrenal cells, StAR is targeted to the inner mitochondria to provide more potent, high activity cholesterol transfer than occurs in COS-1 cells, which may also lack other features specific to adrenal cells. Although StAR functions in these Y-1 cells with a high turnover of at least 400 molecules of cholesterol/StAR/min, more active Y-1 clones, primary adrenal cells, and MA-10 cells exhibit much higher turnover rates, which are apparently less limited by other factors. It remains critical to explain the dependence of cholesterol transfer on newly synthesized StAR. After denatured StAR enters the matrix, it should then complex with the matrix chaperone protein Hsp70, which refolds the protein in an ATP-dependent process (55) . As noted previously, this may account for the ATP requirements of the StAR activity (54) . The related Hsp90 complexes hold steroid receptors in otherwise unfavorable conformations, which however bind ligands more readily (56) . A metastable StAR conformation maintained by Hsp70 could more readily target cholesterol or phospholipids in the inner membrane and even couple the ATPase activity of Hsp70 to generate inner membrane changes that trigger cholesterol transfer. Once dissociated from Hsp70, StAR may be unable to fold into this active conformation, thus accounting for the inactivity of most of the mitochondrial StAR detected with the antibodies. Miller and co-workers (57) have recently drawn attention to the molten globule character of the central section of StAR and have suggested that this plays a critical role in the function. This molten globule structure could well reflect the conformation of StAR when chaperoned by Hsp70.
